← Back to home

CHARCOT-MARIE-TOOTH DISEASE WITH SORBITOL DEHYDROGENASE DEFICIENCY (CMT-SORD)

Clinical trials for CHARCOT-MARIE-TOOTH DISEASE WITH SORBITOL DEHYDROGENASE DEFICIENCY (CMT-SORD) explained in plain language.

Never miss a new study

Get alerted when new CHARCOT-MARIE-TOOTH DISEASE WITH SORBITOL DEHYDROGENASE DEFICIENCY (CMT-SORD) trials appear

Sign up with your email to follow new studies for CHARCOT-MARIE-TOOTH DISEASE WITH SORBITOL DEHYDROGENASE DEFICIENCY (CMT-SORD), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

New drug trial aims to slow debilitating nerve disease

Disease control Not yet recruiting

This study is testing whether a drug called govorestat can provide long-term benefits for people with CMT-SORD, a rare genetic nerve disorder that causes muscle weakness. About 155 patients aged 16-65 will be randomly assigned to receive either the drug or a placebo for up to thr…

Matched conditions: CHARCOT-MARIE-TOOTH DISEASE WITH SORBITOL DEHYDROGENASE DEFICIENCY (CMT-SORD)

Phase: PHASE3 • Sponsor: Applied Therapeutics, Inc. • Aim: Disease control

Last updated Mar 23, 2026 15:14 UTC

CHARCOT-MARIE-TOOTH DISEASE WITH SORBITOL DEHYDROGENASE DEFICIENCY (CMT-SORD)

Get alerted when new CHARCOT-MARIE-TOOTH DISEASE WITH SORBITOL DEHYDROGENASE DEFICIENCY (CMT-SORD) trials appear

New drug trial aims to slow debilitating nerve disease